topics

3/21/26

ABSTRACT

OBJECTIVE: To assess the potential use of plasma microRNAs (miRNAs) in diagnosis of acute venous thromboembolism (VTE).

METHODS: Using BGISEQ-500 sequencing technology, we analyzed the miRNA profile of paired plasma samples from the acute and chronic phases of four patients with unprovoked VTE. Using real-time quantitative polymerase chain reaction (RT-qPCR), we verified nine upregulated named miRNAs in the acute phase in the plasma samples of 54 patients with acute VTE and 39 controls. We then compared the relative expression of the 9 candidate miRNAs between the acute VTE and control group, and plotted the receiver operating characteristic (ROC) curves of the differentially expressed miRNAs. We chose the miRNA with the greatest area under curve (AUC) to evaluate the effect of miRNA on coagulation and platelet function in the plasma samples of 5 healthy volunteers.

RESULTS: The plasma levels of miR-374b-3p, miR-660-5p, miR-378a-3p, miR-425-5p, miR-3613-5p, miR-130b-3p, miR-183-5p, and miR-103b were higher in patients with acute VTE than in the controls, with AUCs of 0.6776, 0.6614, 0.6648, 0.6885, 0.8048, 0.6871, 0.7298, and 0.7498, respectively, and P values of 0.0036, 0.0081, 0.0069, 0.0020,<0.0001,

CONCLUSION: miRNAs can be potential biomarkers for diagnosing acute VTE, and miR-3613-5p may be involved in the formation, coagulation, and platelet functions in acute VTE.

PMID:37334587 | DOI:10.3233/CH-231820

19:55

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

19:55

In reply to this message

PubMed articles on: Cancer & VTE/PE

Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study

J Thromb Haemost. 2023 Jun 16:S1538-7836(23)00493-2. doi: 10.1016/j.jtha.2023.06.009. Online ahead of print.

ABSTRACT

BACKGROUND: Despite high risk of venous thromboembolism (VTE) in patients with pancreatic cancer, there is little data on contact system activation in these patients.

OBJECTIVES: To quantify contact system and intrinsic pathway activation and subsequent VTE risk in patients with pancreatic cancer.

METHODS: Patients with advanced pancreatic cancer were compared to controls. Blood was drawn at baseline and patients were followed for six months. Complexes of proteases with their natural inhibitors, C1-esterase inhibitor (C1-INH), anti-thrombin (AT) or alpha-1 antitrypsin (α1at), were measured for complexes containing kallikrein (PKa:C1-INH), factor XIIa (FXIIa:C1-INH) and factor XIa (FXIa:C1-INH, FXIa:AT, FXIa:α1at). The association of cancer with complex levels was assessed in a linear regression model, adjusted for age, sex and body mass index. In a competing risk regression model we assessed associations between complex levels and VTE.

RESULTS: 109 patients with pancreatic cancer and 22 controls were included. The mean age was 66 years (SD 8.4) in the cancer cohort and 52 years (SD 10.1) in controls. In the cancer cohort, 18 (16.7%) patients developed VTE during follow-up. In the multivariable regression model, pancreatic cancer was associated with increased complexes of PKa:C1-INH (p<0.001),<0.001)<0.001).

CONCLUSION: Complexes of proteases with their natural inhibitors were elevated in patients with cancer. These data suggest that the contact system and intrinsic pathway activation are increased in patients with pancreatic cancer.

PMID:37331518 | DOI:10.1016/j.jtha.2023.06.009